About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNANCT03262220

Total Marrow Irradiation With Volumetric Arc Therapy for Patients Unfit for a 12 Gy TBI

Total body irradiation (TBI) is a standard part of the conditioning regimen for bone marrow transplantation (BMT). Several randomized trials have shown superior outcomes using TBI compared with non TB...

Lead sponsor: Thomas Zilli•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Thomas Zilli, MD

CONTACT

+ 41 79 55 32 563 thomas.zilli@hcuge.ch

Sponsors

Lead Sponsor

Thomas Zilli

Collaborators

University Hospital, Geneva

This is a feasibility prospective pilot study. Ten patients ≥ 40 years with hematologic malignancies prior to Bone Marrow Transplant (BMT) will receive a dose escalated hypofractionated Total Marrow Irradiation (TMI) (12 Gy in 3 fractions, daily, on 3 consecutive days). The current project is a joint initiative in translational and clinical medical research between the Radiation-oncology workgroup and the Bone Marrow transplant workgroup of University Hospitals of Geneva (HUG).

Age

40 - 80 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Karnofsky performance status ≥ 70
•Presence of any kind of haematological malignancy in complete remission (CR1, CR2 ore CR3) at time of transplantation, with the exception of patients with myelodysplastic syndrome.
•Patients that are scheduled for a BMT either using stem cell derived from bone marrow or peripheral blood stem cells.
•Candidates to receive a 10 Gy TBI treatment.
•Ability to stay still and lying on the treatment couch for at least 45 minutes.
•Informed Consent as documented by signature.

Exclusion Criteria

•Karnofsky performance status \<70 intended as a patient unable to work; able to live at home and care for most personal needs with varying amount of assistance needed.
•Concurrent treatment with other experimental drugs or other anti-cancer therapy.
•Participation in another clinical trial and any concurrent treatment with any investigational drug within 4 weeks prior to trial entry/randomisation.
•Inability to comply with study and follow-up procedures.

Related studies

RECRUITINGPhase 2

Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial

NCT06510699 · Fungal Infection, Haematological Malignancy, and more

RECRUITINGPhase 1/2

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

NCT04068597 · Haematological Malignancy, Acute Myeloid Leukemia, and more

Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management With Early Discharge of Patients With Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital

NCT06814405 · Haematological Malignancy

Active Not Recruiting

Effect of the BioFire FilmArray (BCID2) for the Rapid Detection of Bloodstream Infection in Haematologic Patients With Febrile Neutropenia

NCT06787326 · Haematological Malignancy, Febrile Neutropenia, and more

Not Yet RecruitingPhase 2/3

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

NCT07440290 · Haematological Malignancy, Malignant Neoplasm, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 14, 2020Terms

Trial snapshot

StatusUNKNOWN

PhaseNA

Enrollment10

Start dateApr 2017

Last updatedMay 14, 2020

Condition

Haematological Malignancy

Locations shown

University Hospital of Geneva

Geneva

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 14, 2020Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions